The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Linda D. Cardozo

King's College Hospital

Denmark Hill

London SE5 9RS

UK

[email]@compuserve.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • King's College Hospital, Denmark Hill, London SE5 9RS, UK. 2004 - 2010
  • Department of Urogynaecology, King's College Hospital, London, W1G 6HP, UK. 2005 - 2009
  • 8 Devonshire Place, London, W1G 6HP, UK. 2009
  • King's College School of Medicine and Dentistry, London, UK. 2001

References

  1. Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. Cardozo, L., Khullar, V., El-Tahtawy, A., Guan, Z., Malhotra, B., Staskin, D. BMC. Urol (2010) [Pubmed]
  2. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? Cardozo, L., Khullar, V., Wang, J.T., Guan, Z., Sand, P.K. BJU Int. (2010) [Pubmed]
  3. Urinary urgency - translating the evidence base into daily clinical practice. Cardozo, L., Chapple, C.R., Dmochowski, R., Fitzgerald, M.P., Hanno, P., Michel, M.C., Staskin, D., Van Kerrebroeck, P., Wyndaele, J.J., Yamaguchi, O., Yoshida, M. Int. J. Clin. Pract. (2009) [Pubmed]
  4. Considerations for the management of urgency symptoms in patients with overactive bladder syndrome. Cardozo, L.D., Van Kerrebroeck, P.E., Staskin, D.R. World. J. Urol (2009) [Pubmed]
  5. Urgency as the cardinal symptom of overactive bladder: a critical analysis. Cardozo, L., Chapple, C., Wein, A. World. J. Urol (2009) [Pubmed]
  6. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. Cardozo, L., Hessdörfer, E., Milani, R., Arañó, P., Dewilde, L., Slack, M., Drogendijk, T., Wright, M., Bolodeoku, J. BJU Int. (2008) [Pubmed]
  7. The overactive bladder syndrome: treating patients on an individual basis. Cardozo, L. BJU Int. (2007) [Pubmed]
  8. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Cardozo, L., Castro-Diaz, D., Gittelman, M., Ridder, A., Huang, M. Int. Urogynecol. J. Pelvic. Floor. Dysfunct (2006) [Pubmed]
  9. Increased warning time with darifenacin: a new concept in the management of urinary urgency. Cardozo, L., Dixon, A. J. Urol. (2005) [Pubmed]
  10. Neurobiology of stress urinary incontinence: new insights and implications for treatment. Cardozo, L. J. Obstet. Gynaecol (2005) [Pubmed]
  11. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Cardozo, L., Lose, G., McClish, D., Versi, E. Acta. Obstet. Gynecol. Scand (2004) [Pubmed]
  12. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Cardozo, L., Lisec, M., Millard, R., van Vierssen Trip, O., Kuzmin, I., Drogendijk, T.E., Huang, M., Ridder, A.M. J. Urol. (2004) [Pubmed]
  13. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Cardozo, L., Lose, G., McClish, D., Versi, E., de Koning Gans, H. Int. Urogynecol. J. Pelvic. Floor. Dysfunct (2001) [Pubmed]
 
WikiGenes - Universities